<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02444572</url>
  </required_header>
  <id_info>
    <org_study_id>ENOXACARE_med14</org_study_id>
    <nct_id>NCT02444572</nct_id>
  </id_info>
  <brief_title>Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox®</brief_title>
  <acronym>ENOXACARE</acronym>
  <official_title>Comparison of Thromboembolic Events in Patients Undergoing Gastrointestinal Cancer Surgery and Thromboprophylactic Treatment With Two Enoxaparin Formulations (ENOXA® vs Lovenox®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Les Laboratoires des Médicaments Stériles</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Les Laboratoires des Médicaments Stériles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, monocentric, randomized, parallel group, rater-blinded study using two
      formulations of Enoxaparin sodium (ENOXA® vs LOVENOX®) to compare the thromboembolic events
      (symptomatic and asymptomatic) in patients undergoing gastrointestinal cancer surgery and
      thromboprophylactic treatment with either Enoxaparin formulations.

      The study has a secondary focus as to evaluate the immunogenicity of the two formulations of
      Enoxaparin through a subgroup analysis.

      Study followup duration is up to 30 days post surgical procedure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of asymptomatic Deep Venous Thrombosis (DVT)</measure>
    <time_frame>7 - 10 days postoperative</time_frame>
    <description>To compare the incidence of asymptomatic DVT, assessed by Echo Doppler of the lower limbs, between the two study treatment arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of symptomatic thromboembolic events</measure>
    <time_frame>30 days postoperative</time_frame>
    <description>Compare the incidence of symptomatic DVT and pulmonary embolism (PE) between the two study treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>30 days postoperative</time_frame>
    <description>To compare the safety of both the study of products</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of both Enoxaparin formulations immunogenicity</measure>
    <time_frame>0 -10 days postoperative</time_frame>
    <description>To compare the levels of platelet factor 4 (PF4)-Heparin complex antibodies an platelet count between the two study treatment arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Gastrointestinal Neoplasms</condition>
  <condition>Thromboembolic Event</condition>
  <arm_group>
    <arm_group_label>ENOXA® group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients under ENOXA® 4000 IU according to randomization:
Administer ENOXA® 4000 IU (Enoxaparin 4000 IU) per day, regardless of the patient's weight at inclusion
Start injections 12 hours after the surgical procedure
Administer ENOXA® subcutaneously
The administration of ENOXA® should be at the same time on a daily basis for 30 successive days as per the american and french clinical guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LOVENOX® group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients under LOVENOX® 4000 IU according to randomization:
Administer LOVENOX® 4000 IU (Enoxaparin 4000 IU) per day, regardless of the patient's weight at inclusion
Start injections 12 hours after the surgical procedure
Administer LOVENOX® subcutaneously
The administration of LOVENOX® should be at the same time on a daily basis for 30 successive days as per the american and french clinical guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin 4000 IU</intervention_name>
    <arm_group_label>ENOXA® group</arm_group_label>
    <arm_group_label>LOVENOX® group</arm_group_label>
    <other_name>ENOXA®</other_name>
    <other_name>LOVENOX®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female over 18 years

          -  Gastrointestinal (GI) Cancer

          -  Elective or emergency surgery

          -  Preventive administration of enoxaparin sodium

        Exclusion Criteria:

          -  Patients participating in another study

          -  Unfractionated heparin (UFH) use up to 30 days prior to surgical procedure

          -  Renal failure with creatinine clearance &lt;30 ml / min

          -  Known history of peripheral venous thrombosis and/or deep venous thrombosis in the 3
             months prior to inclusion

          -  Pregnant or breastfeeding women or women of childbearing age not using medically
             accepted contraceptive method

          -  Anticoagulant use in the 3 months prior to inclusion

          -  Patients with known haemostatic disorder

          -  Patients not consenting to participate in the study, or not capable of understanding
             its objectives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chadli DZIRI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles Nicolle Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chadli DZIRI, MD</last_name>
    <phone>+216 71 569 047</phone>
    <email>chedli.dziri@rns.tn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charles Nicolle Hospital</name>
      <address>
        <city>Tunis</city>
        <state>Tunis BAB Souika</state>
        <zip>1006</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chadli DZIRI, MD</last_name>
      <phone>216 71 569 047</phone>
      <email>chadli.dziri@planet.tn</email>
    </contact>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 7, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2015</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Enoxaparin</keyword>
  <keyword>Immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

